NTRB
Nutriband Inc. Common Stock
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Best Orthopedic Devices Stocks 2026 →
Nutriband (NTRB) Stock: Buy, Sell, or Hold?
$6.10
+0.13 (+2.18%)
▲
5d:
+9.91%
30d:
-2.71%
90d:
+88.85%
QUANTITATIVE VERDICT
BUY
MODERATE Confidence (82%)
Quality Score
55/100
Position
FAIR
30-Day Fair Range
$5.80 – $6.42
Position: FAIR
Forward P/E & Valuation
4.2x
STRETCHED
vs 3.1x historical avg
Wall Street Target
$15.00
+145.9% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$5.28 / $6.52
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
💡 BUY OPPORTUNITY: NTRB shows positive signals but monitor for confirmation. Market pricing in 10.8% annual growth which appears achievable. Moderate conviction.
Get Alerted When NTRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$6.30
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$3.91
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 3.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NTRB is currently trading at $6.10, which is considered fair relative to its 30-day fair value range of $5.80 to $6.42. From a valuation perspective, the stock is trading at a premium (Forward PE: 4.2) compared to its historical average (3.1). At these levels, the market is pricing in 10.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NTRB is in a strong uptrend. Immediate support is located at $5.28, while resistance sits at $6.51.
Market Sentiment: NTRB scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $15.00 (+145.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NTRB is in a strong uptrend. Immediate support is located at $5.28, while resistance sits at $6.51.
Market Sentiment: NTRB scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $15.00 (+145.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$5.80 -
$6.42
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.4%
Trading Range & Key Levels
30-Day Trading Range
$5.80 -
$6.42
Current vs Trading Range
FAIR
Support Level
$5.28
Resistance Level
$6.52
Current Trend
Strong Uptrend
Technical data as of
Nov 13, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 145.9% below Wall St target ($15.00)
- NEUTRAL: Trading at premium valuation - market expects 10.8% growth which is achievable
- BULLISH: Bottoming setup score 63/100 — corrected, stabilizing, and turning up
Fundamental Context
Forward P/E (Next Year Est.)
4.21
Wall Street Target
$15.00
(+145.9%)
Revenue Growth (YoY)
-29.7%
Valuation Premium vs History
+10.8% premium
PE vs Historical
4.2 vs 3.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+10.8%
(market-implied from PE analysis)
1-Year Target
$6.76
(+11%)
2-Year Target
$7.49
(+23%)
3-Year Target
$8.30
(+36%)
3-Yr Target (if PE normalizes)
(PE: 4→3)
PE COMPRESSION
$6.11
(+0%)
Earnings growth offset by PE compression
Share NTRB Analysis
Share this live NTRB analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (NTRB)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 10, 2026
Daily AI digest
AI Retail Discussion Summary:
Trader on StockTwits expresses bullish sentiment towards $NTRB, expecting a price pop.
Key Retail Themes:
bullish price prediction
trading opportunity
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 15, 2026 12:20 AM ET
Data refreshes hourly during market hours. Next update: 1:20 AM
Data refreshes hourly during market hours. Next update: 1:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NTRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
25 analysts |
$261 | 38 SELL |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$194 | 41 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 43 HOLD |
|
SNDX
Syndax Pharmaceuticals I… |
STRONG BUY
12 analysts |
$35 | 63 BUY |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 43 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive NTRB Research Pages
